Liquid Crystal Nanoparticles: A Novel Strategy for Improved Cancer Treatment

The primary cause of mortality globally is cancer, which is defined as aberrant cell growth and proliferation. It is an incurable condition in which the person's environment interacts with the DNA to cause many alterations. There are many different therapy options for cancer; however, innovative drug delivery systems, or NDDS, are a newer kind of medicine. NDDS, which mostly consists of liposomes, niosomes, transferosomes, phytosomes, microspheres, nanoparticles, and liquid crystal nanoparticles, is used to treat cancer. Lyotropic nonlamellar liquid crystalline nanoparticles (LCNs) are thought to be efficient drug delivery devices because of their unique structural characteristics. The interior nanostructure of LCNs is highly organized and thermodynamically stable, making them useful for forming a matrix for prolonged drug release. They provide us with a safer, more effective, and less hazardous substitute for current medication delivery techniques. Because LCNPs are targeted specific, harmless to normal cells, enhanced drug solubility and bioavailability, improved drug stability, and tumor-specificity, they are now being investigated for application in a variety of cancers, including lung, prostate, and breast cancer. The current study primarily addresses LNCs, including their categories, benefits and drawbacks, mode of action, structure, use, and prospects for the future. Additionally, we have included a synopsis of how LCNPs are used in cancer therapies. LNCs have the potential to be a viable method for the focused therapy of cancer and a capable substitute for the way that cancer is now treated.